Urogen Pharma (0XOD) Stock Statistics & Valuation Metrics

Urogen Pharma has a market cap or net worth of $685.62M. The enterprise value is $246.01M.

Urogen Pharma has 46,107,452 shares outstanding. The number of shares has decreased by -2.65% in one year.

Urogen Pharma’s return on equity (ROE) is 14.41 and return on invested capital (ROIC) is -41.29%.

The current PE Ratio of Urogen Pharma is -3.60. Urogen Pharma’s PEG ratio is 0.54.

In the last 12 months, Urogen Pharma had revenue of 90.40M and earned -126.87M in profits. Earnings per share was -2.96.

In the last 12 months, operating cash flow was -107.06M and capital expenditures -339.00K, giving a free cash flow of -107.39M billion.

Urogen Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Urogen Pharma upcoming earnings date is Aug 19, 2025, TBA Not Confirmed.

Urogen Pharma as a current ratio of 6.01, with Debt / Equity ratio of -111.70%

In the past 12 months, Urogen Pharma has paid 2.83M in taxes.

Urogen Pharma EV to EBITDA ratio is -3.70, with an EV/FCF ratio of -4.20.

Urogen Pharma has $195.89M in cash and marketable securities with $124.95M in debt, giving a net cash position of -$70.94M billion.

Gross margin is 88.11%, with operating margin of -107.06%, and net profit margin of -140.35%.

The average price target for Urogen Pharma is $33.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy